tradingkey.logo

Genfit SA

GNFT
View Detailed Chart
4.065USD
-0.045-1.09%
Close 11/11, 16:00ETQuotes delayed by 15 min
203.26MMarket Cap
--P/E TTM

Genfit SA

4.065
-0.045-1.09%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.09%

5 Days

+0.37%

1 Month

-4.36%

6 Months

-5.47%

Year to Date

+9.42%

1 Year

-22.28%

View Detailed Chart

TradingKey Stock Score of Genfit SA

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is low. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Genfit SA's Score

Industry at a Glance

Industry Ranking
269 / 501
Overall Ranking
480 / 4682
Industry
Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Strong Buy
Current Rating
8.683
Target Price
+111.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Genfit SA Highlights

StrengthsRisks
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 147.99% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 62.29M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 145.37, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 80.73K shares, decreasing 89.49% quarter-over-quarter.

Genfit SA News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Genfit SA Info

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Ticker SymbolGNFT
CompanyGenfit SA
CEOMr. Pascal Prigent
Websitehttps://www.genfit.fr/
KeyAI